Trial · NCT03285711
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in Urine Protein From Baseline (Day 1) to Week 16 | Lanraplenib 30 mg | -2.8 | percent change | ||
| Percent Change in Urine Protein From Baseline (Day 1) to Week 16 | Filgotinib 200 mg | -51.2 | Standard Deviation 25.67 | percent change | |
| Change From Baseline (Day 1) in Urine Protein at Week 16 | Lanraplenib 30 mg | -0.177 | g/day | ||
| Change From Baseline (Day 1) in Urine Protein at Week 16 | Filgotinib 200 mg | -2.151 | Standard Deviation 2.2591 | g/day | |
| Change From Baseline (Day 1) in Estimated Glomerular Filtration Rate (eGFR) at Week 16 | Lanraplenib 30 mg | -59.4 | mL/min/1.73 m^2 | ||
| Change From Baseline (Day 1) in Estimated Glomerular Filtration Rate (eGFR) at Week 16 | Filgotinib 200 mg | -2.0 | Standard Deviation 11.35 | mL/min/1.73 m^2 | |
| Change From Baseline (Day 1) in Urine Protein Creatinine Ratio (UPCR) at Week 16 | Lanraplenib 30 mg | -4.407 | mg/mg | ||
| Change From Baseline (Day 1) in Urine Protein Creatinine Ratio (UPCR) at Week 16 | Filgotinib 200 mg | -0.808 | Standard Deviation 0.7539 | mg/mg | |
| Percentage of Participants With Partial Remission at Week 16 | Lanraplenib 30 mg | 0 | percentage of participants | ||
| Percentage of Participants With Partial Remission at Week 16 | Filgotinib 200 mg | 50.0 | percentage of participants | ||
| Percentage of Participants With Complete Remission at Week 16 | Lanraplenib 30 mg | 0 | percentage of participants | ||
| Percentage of Participants With Complete Remission at Week 16 | Filgotinib 200 mg | 0 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03285711/results